Peter Kies

Peter Kies (finance chief) discloses dealings in Inovio Pharmaceuticals, Inc. to SEC (Form 4). Over a trading history stretching from 5 March 2016 to 26 February 2026, the count stands at 75 filings.

Sales make up the whole of the open-market record (10 sales, €2.6M). Outside the open market, there are 29 share grants and 36 option exercises.

Most recently, on 27 February 2026, the filings show an option exercise in Inovio Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.